Recommended Free Tools
Investing in a clinical-stage biotech means accepting that a drug candidate may fail, take longer or cost more to develop than expected, or never become a commercial product. Even if a trial succeeds, FDA review, financing, manufacturing, intellectual property, competition, and commercial execution remain separate risks. A company’s clinical phase is an evidence milestone—not a stand-alone measure of its chance of success.
What can go wrong in a clinical trial?
A candidate may not show the intended benefit, cause unacceptable safety problems, or produce results too uncertain to support the next development step. A trial can also fail to answer its intended question because of its design, duration, enrollment, or analysis. Early or interim results are not guarantees of later or final results.
The U.S. Food and Drug Administration describes a typical path from small, early Phase 1 studies to larger, later Phase 3 studies. Phase 1 focuses on safety and dosage; later studies assess efficacy and adverse reactions in larger groups. Each phase tests different questions, and advancing a candidate does not guarantee that it will succeed in the next phase or receive approval.
As general phase-transition figures, the FDA’s clinical research page reports that approximately 33% of drugs move to the next phase after Phase 1 and approximately 25–30% after Phase 2. These FDA figures, accessed in 2026, describe broad transitions—not the probability that a particular drug will succeed, gain approval, or generate a return. They should not be applied as company-specific forecasts.
Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Scan for outdated or missing drivers - takes under a minute3Clear out junk files and repair common Windows errors#1 Best Overall
For an issuer-specific example of the uncertainty, Celldex Therapeutics’ 2025 Form 10-K warns that early or interim clinical results may not predict later-stage or final trial results. That is the company’s risk disclosure, not a universal failure rate or a prediction about Celldex’s outcome.
Why do trial design and data interpretation matter?
A trial’s result is meaningful only in light of the question it was built to answer. The FDA identifies choices such as participant eligibility, sample size, study duration, control group, drug administration, and the data collected and analyzed as elements of clinical research design. Investors should look beyond a headline result and ask what the study actually tested.
- Population: Which patients were eligible, and how closely do they resemble the patients the company hopes to treat?
- Comparator and dose: Was the candidate compared with a control, and what treatment or dose did each group receive?
- Endpoints and analysis: What was the primary endpoint, and were the analyses specified in advance?
- Timing and completeness: Is the reported result interim or final, and how long were participants followed?
- Enrollment: Is the study recruiting as planned, and could enrollment challenges affect timing or the populations represented?
The FDA’s October 2022 final guidance on multiple endpoints explains that analyzing more endpoints can increase the risk of false conclusions unless multiplicity is handled appropriately. A favorable result on one measure is therefore not enough to understand the evidence; investors need to know which endpoint was primary and how the analysis treated the others.
Why is FDA review a separate hurdle?
Clinical progress does not itself authorize a drug for sale. After a developer submits an application supported by preclinical and clinical evidence, the FDA reviews the submitted material before deciding whether to approve the drug for its intended use. The application review is a distinct stage, and the agency’s decision depends on the evidence and the proposed use presented in that application.
A delay, a request for additional evidence, a rejection, or approval for a narrower use than investors expected can change a company’s prospects. The FDA’s general review-process description explains the hurdle but cannot establish the likely decision for an individual candidate. That assessment requires current, candidate-specific evidence and regulatory history.
How can financing needs affect shareholders?
A company without approved products may have little or no product revenue while paying for trials and operations. If it needs more capital, it may issue shares, diluting existing shareholders’ ownership. If acceptable financing is unavailable, the company may have to delay, reduce, or end programs.
These are risks identified in specific company filings, not claims that every biotech has the same finances. Apogee Therapeutics’ 2025 Form 10-K says it expects to need substantial additional capital and warns that a funding shortfall could force program delays, reductions, or elimination. Celldex Therapeutics’ 2025 Form 10-K describes potential dilution from additional equity financing and warns that financing may not be available on acceptable terms.
When assessing a particular company, use its latest filings rather than relying on a previously stated runway estimate. Check cash, cash equivalents and marketable securities; operating cash use; debt and covenants; upcoming trial milestones; committed partner funding; recent offerings or shelf registrations; and the assumptions behind management’s runway estimate. A runway can change as spending, trial timing, and financing conditions change.
Free tools Windows power users keep installed
One-click scans. No signup required.
What operational, manufacturing, and intellectual-property risks remain?
Some developers rely on outside organizations for trial sites, research services, manufacturing, licensing, or collaboration. A delay, quality problem, disagreement, or loss of a critical provider can interfere with development or supply. Apogee Therapeutics’ 2025 Form 10-K identifies third-party manufacturing reliance among its disclosed risks.
Rank #4
Intellectual-property rights also require company-specific review. Patent protection may be uncertain, and licenses or collaboration agreements can affect what rights a company holds and what obligations it must meet. Apogee’s filing identifies uncertainty around patents and other proprietary rights; it does not establish the status of another company’s protections.
- Identify which critical functions are performed internally and which are outsourced.
- Check whether development or supply depends on a single provider, partner, or license.
- Review the company’s disclosed rights, obligations, and uncertainties in relevant agreements and filings.
Why does approval not guarantee commercial success?
An approved product still has to be made, distributed, supported, and used in clinical practice. A company may need additional capital or a commercial partner to handle manufacturing, market access, and ongoing safety obligations. The FDA’s drug-review description includes manufacturing information in the material considered during review, but clearing review does not by itself establish that a company can successfully execute every commercial step.
Commercial prospects also depend on the product’s intended use and the market it can reach. The available evidence here does not establish a numerical probability that an approved biotech product will succeed commercially, so a percentage should not be inferred from the phase-transition figures.
What should you compare before investing?
Use the same questions for each company rather than treating “biotech” as a single risk category. The answers should come from current company filings, trial information, and relevant FDA materials; they are diligence questions, not a formula for predicting returns.
| Area | Questions to examine |
| Evidence and stage | What has been observed in humans? Is the evidence interim or final, and what remains untested? |
| Trial design | Who is enrolled? What are the comparator, endpoints, analysis plan, duration, and enrollment status? |
| Regulatory path | What evidence, submissions, or study requirements remain before an application and decision? |
| Financing | What cash and spending does the latest filing show? What assumptions support management’s runway, and what funding could dilute holders or constrain programs? |
| Execution and partners | Which clinical, manufacturing, or other essential functions depend on third parties? |
| Intellectual property | What rights does the company disclose, and what uncertainties or contractual obligations affect them? |
| Commercial readiness | If approved, how would the product be manufactured, distributed, accessed by patients, and supported? |
Company filings provide examples of risks that particular issuers identify; they do not show that every company faces the same circumstances. Financial statements, trial status, agency policy, and share counts can change, so company-specific judgments should be based on current records.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
